Tumor Imaging Metrics

项目总结(见说明)： 在上一次CCSG提交的报告中，肿瘤成像指标核心被批准为开发中的核心。这个 肿瘤成像指标核心(TIMC)为参加肿瘤临床试验的患者提供对治疗反应的客观评估。支持所有主要的放射评估标准，包括：RECIST(1.0和1.1)、WHO、IWRC、Cheson、SUV、Choi、3D Volume和IRRC。对于每个患者，目标和非目标 根据评估标准指南选择病变，并进行纵向跟踪。 要测量的扫描通过DICOM成像网络从DF/HCC站点传输到中心核心实验室。CT、MR和PET成像研究的定量分析在各种特定型号的工作站上进行。扫描分析后，测量结果由哈佛大学教职放射科医生和/或核医学医生审查和最终确定。测量结果存储在TIMC中 数据库放在一个安全的网站上，并可由经授权的审判工作人员在线查看。定量测量用于确定肿瘤对治疗的反应，并最终指导患者护理。 试验的汇总统计数据以及单个患者的测量数据都提供了出来。试验人员可以方便地在线订购扫描分析请求。用户通过其所在机构的用户名和密码(单点登录)进行身份验证。与电费/电费相比，电费非常合理。 从DF/HCC外部提供的其他选项。 导演(S)：戈登·J·哈里斯(Gordon J.Harris)博士和安妮·D·范登·艾比勒(Annick D.Van den Abbeele) 类别：4.03(临床-放射及肿瘤影像) 管理：联合(癌症中心和机构)

PROJECT SUMMARY (See instructions): The Tumor Imaging Metrics Core was approved as a developing core in the last CCSG submission. The Tumor Imaging Metrics Core (TIMC) provides objective assessment of response to treatment for patients enrolled in oncology clinical trials. All major radiological assessment criteria are supported including: RECIST (1.0 and 1.1), WHO, IWRC, Cheson, SUV, Choi, 3D Volume and irRC. For each patient, target and nontarget lesions are selected according to the assessment criteria guidelines and are tracked longitudinally. Scans to be measured are transferred from DF/HCC sites to the central Core lab via DICOM imaging network. Quantitative analysis of CT, MR and PET imaging studies are performed on a variety of modalityspecific workstations. After scans are analyzed, the measurement results are reviewed and finalized by Harvard faculty radiologists and/or nuclear medicine physicians. Measurement results are stored in the TIMC database on a secure website and are viewable online by authorized trial staff. The quantitative measurements are used to determine tumor response to treatment and ultimately guide patient care. Summary statistics for the trial are presented as well as individual patient measurements. Requests for scan analysis can be conveniently ordered on-line by the trial staff. Users are authenticated via their home institution's username and password (single sign-on). Rates for sen/ices are very reasonable compared to other options available from outside DF/HCC. Director(s): Gordon J. Harris, PhD"^"and Annick D. Van den Abbeele, MD Category: 4.03 (Clinical - Radiology and Tumor Imaging) Management: Joint (Cancer Center and Institutional)